Get the Stockscreener App
32.97
1.43%
-0.48
After Hours:
37.00
4.03
+12.22%
Veracyte Inc stock is traded at $32.97, with a volume of 1.49M.
It is down -1.43% in the last 24 hours and up +2.23% over the past month.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
See More
Previous Close:
$33.45
Open:
$33.75
24h Volume:
1.49M
Relative Volume:
1.66
Market Cap:
$2.63B
Revenue:
$517.15M
Net Income/Loss:
$66.35M
P/E Ratio:
40.15
EPS:
0.8212
Net Cash Flow:
$126.63M
1W Performance:
-1.38%
1M Performance:
+2.23%
6M Performance:
-28.39%
1Y Performance:
+5.27%
1-Day Range:
$32.21
$34.38
1-Week Range:
$31.16
$34.38
52-Week Range:
$22.61
$50.71
Veracyte Inc Stock (VCYT) Company Profile
Name
Veracyte Inc
Sector
Industry
Phone
(650) 243-6300
Address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
32.97 | 2.67B | 517.15M | 66.35M | 126.63M | 0.8212 |
TMO
Thermo Fisher Scientific Inc
|
466.76 | 171.91B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
174.63 | 123.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.97 | 44.73B | 4.30B | 1.06B | 1.04B | 13.08 |
WAT
Waters Corp
|
342.75 | 29.63B | 3.17B | 642.63M | 516.49M | 10.77 |
A
Agilent Technologies Inc
|
117.53 | 31.70B | 7.07B | 1.29B | 993.00M | 4.5355 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Jefferies | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Underweight |
| Oct-20-25 | Initiated | Canaccord Genuity | Hold |
| Mar-20-25 | Initiated | Craig Hallum | Buy |
| Dec-05-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-16-24 | Initiated | UBS | Buy |
| Oct-10-24 | Initiated | Guggenheim | Buy |
| Feb-23-24 | Reiterated | Needham | Buy |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Nov-18-21 | Resumed | Goldman | Buy |
| Jun-15-21 | Initiated | Raymond James | Outperform |
| Feb-18-21 | Resumed | Needham | Buy |
| Jan-28-21 | Initiated | Truist | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-09-20 | Initiated | Morgan Stanley | Underweight |
| Jul-31-19 | Initiated | Lake Street | Buy |
| Jul-02-19 | Initiated | Needham | Buy |
| Nov-29-18 | Downgrade | Janney | Buy → Neutral |
| Oct-31-18 | Upgrade | Janney | Neutral → Buy |
| Nov-07-17 | Downgrade | Janney | Buy → Neutral |
| Nov-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-31-17 | Resumed | BTIG Research | Buy |
| Nov-14-16 | Resumed | Leerink Partners | Outperform |
| Dec-18-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-11-15 | Reiterated | Leerink Partners | Outperform |
| Nov-26-13 | Initiated | William Blair | Outperform |
View All
Veracyte Inc Stock (VCYT) Latest News
Veracyte Inc (NASDAQ:VCYT) Smashes Q1 Estimates and Raises Full-Year Guidance, Shares Surge - ChartMill
Veracyte (VCYT) Q1 2026 Earnings Transcript - AOL.com
Veracyte Q1 2026 slides: EPS beats by 57%, guidance raised - Investing.com
Full Transcript: Veracyte Q1 2026 Earnings Call - Benzinga
Veracyte: Q1 Earnings Snapshot - kare11.com
Earnings Flash (VCYT) Veracyte, Inc. Reports Q1 Revenue $139.1M, vs. FactSet Est of $130.4M - marketscreener.com
Earnings Flash (VCYT) Veracyte, Inc. Posts Q1 Adjusted EPS $0.52 per Share - marketscreener.com
Cancer test maker Veracyte posts $28.7M profit, raises outlook - Stock Titan
Veracyte (NASDAQ: VCYT) boosts Q1 profit and raises 2026 outlook - Stock Titan
Veracyte Announces First Quarter 2026 Financial Results - Business Wire
Veracyte earnings loom: Investors watch for TrueMRD launch details By Investing.com - Investing.com South Africa
Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.16%: Read This Before Placing a Bet - Yahoo! Finance Canada
MSN Money - MSN
Morgan Stanley cuts Veracyte stock price target on valuation methodology - Investing.com
A Look At Veracyte (VCYT) Valuation As New Decipher Bladder And Prostate Data Heads To AUA 2026 - Yahoo Finance
Veracyte Inc (NASDAQ:VCYT) GARP Analysis Reveals Strong Growth at a Reasonable Price - ChartMill
Vanguard reports 5.2% stake in Veracyte (VCYT) via Schedule 13G - Stock Titan
Earnings Preview: Veracyte to Report Financial Results Post-market on May 05 - Moomoo
Will New Decipher Evidence at AUA 2026 Shift Veracyte's (VCYT) Precision Oncology Narrative? - Sahm
Vanguard Portfolio Management (VCYT) reports 4.51M shares, 5.67% stake - Stock Titan
If you invested $1000 in Veracyte a decade ago, this is how much it'd be worth now - MSN
Veracyte Inc (NASDAQ:VCYT): A High-Growth Biotech Stock Poised for a Technical Breakout - ChartMill
Veracyte (VCYT) to Present Extensive Research at AUA 2026 Annual Meeting - GuruFocus
Veracyte (VCYT) to Release Earnings on Tuesday - MarketBeat
Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers - Business Wire
Veracyte (VCYT) Recently Broke Out Above the 50-Day Moving Average - Yahoo Finance
If You Invested $1000 in Veracyte a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Veracyte (VCYT) down 15.4% since last earnings report: Can it rebound? - MSN
AEGON ASSET MANAGEMENT UK Plc Has $20.60 Million Position in Veracyte, Inc. $VCYT - MarketBeat
Q3 2025 Veracyte Inc Earnings Call Transcript - GuruFocus
Q1 2025 Veracyte Inc Earnings Call Transcript - GuruFocus
Q2 2025 Veracyte Inc Earnings Call Transcript - GuruFocus
Veracyte Inc at Piper Sandler Healthcare Conference (Virtual)Pre-recorded Fireside Chat Transcript - GuruFocus
Veracyte Inc (VCYT) Stock Up 3.5% and Still Undervalued -- GF Sc - GuruFocus
Veracyte (VCYT) loses 20.0% in 4 weeks, here's why a trend reversal may be around the corner - MSN
VCYT Price Today: Veracyte, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Emerging Sub-Segments Transforming the Thyroid Cancer Diagnostics Market Landscape - openPR.com
VCYT Veracyte delivers triple digit Q4 2025 EPS beat and 16 percent annual revenue growth despite mild stock dip.EBITDA Margin - Cổng thông tin điện tử Tỉnh Sơn La
Veracyte (NASDAQ: VCYT) asks investors to back directors, auditor and larger equity plan - Stock Titan
[ARS] VERACYTE, INC. SEC Filing - Stock Titan
Emerging Growth Patterns Driving Expansion in the Liquid Biopsy for Cancer Diagnostics Market - openPR.com
VCYT Maintained by Canaccord Genuity -- Price Target Lowered to $40 - GuruFocus
CCORF Maintains Veracyte(VCYT.US) With Hold Rating, Cuts Target Price to $40 - Moomoo
Veracyte Price Target Cut to $40.00/Share From $43.00 by Canaccord Genuity - Moomoo
Veracyte (NASDAQ:VCYT) Given New $40.00 Price Target at Canaccord Genuity Group - MarketBeat
Is Veracyte (VCYT) Offering Value After Mixed Returns And Conflicting Valuation Signals - Yahoo Finance
Veracyte, Inc. (NASDAQ:VCYT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Assessing Veracyte (VCYT) Valuation After A Recent Share Price Rebound - Sahm
Sumitomo Mitsui Trust Group Inc. Sells 224,185 Shares of Veracyte, Inc. $VCYT - MarketBeat
Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026 - BioSpace
Veracyte Inc Stock (VCYT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):